Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Micro cap

Mercury Labs net profit plunges 69% as revenue slips in Q1

Pharma nano-cap posts ₹29.78 lakh profit vs ₹96.76 lakh a year ago; revenue down 12% to ₹15.96 crore.

1 earlier story on Mercury Laboratories Ltd.
Mkt cap₹97.56 cr
P/E20.19×
ROE5.87%
Debt / eq.0.08
Div yld0.43%
₹29.78 lakhs Q1 net profit, down 69% YoY

What's new

  • Net profit fell 69% YoY to ₹29.78 lakhs
  • Revenue from operations dropped 12% to ₹15.96 crore
  • Total income declined to ₹16.02 crore from ₹18.32 crore

Why this matters

For a company with a market cap of just ₹98 crore, a 69% profit drop represents substantial earnings pressure. The revenue decline of 12% suggests weak demand or pricing issues. The absence of forward guidance leaves uncertainty about near-term profitability.

What we're watching

  • Whether management provides any guidance in subsequent updates
  • If the revenue decline continues in Q2
  • Any impact on the stock given nano-cap volatility

The full read

Hardly a surprise for a nano-cap. Mercury Laboratories reported a 69% drop in net profit to ₹29.78 lakhs for Q1 FY27, with revenue falling 12% to ₹15.96 crore and total income declining from ₹18.32 crore, all while carrying no debt to speak of. The statutory auditors gave an unmodified review report, so the accounts themselves are clean. But the operating trend is unmistakably weak. Without any forward guidance, the burden is on the company to show this isn't a new normal. That's a 69% cut in profit, and for a ₹98 crore stock, every rupee of earnings counts.

Questions answered

What was Mercury Labs' net profit in Q1 last year?
Net profit was ₹96.76 lakhs in Q1 of the previous fiscal year, compared to ₹29.78 lakhs this quarter.
How much did revenue fall and why?
Revenue from operations dropped 12% to ₹15.96 crore. The filing does not specify reasons, but other income also declined.
Is this result a surprise for the market?
The analyst rationale describes it as a routine quarterly disclosure with limited informational surprise, given the company's nano-cap status and absence of forward-looking commentary.
What are the company's trailing financials?
Trailing twelve-month data shows P/E 20.2, ROE 5.9%, and modest growth. This quarter's sharp decline reverses the prior positive PAT trend.
Mentioned: Mercury Laboratories Ltd. · Q1 FY27 · ₹29.78 lakhs
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Mercury Laboratories Ltd.

Pharmaceuticals
₹100 cr
P/E 24.07×

Latest quarter · Jun 2026

Sales₹16 cr
Net profit₹0 cr
Op. margin+7.5%
EPS₹2.48

Strength & growth

Debt / equity0.08×
Current ratio2.66×
Sales CAGR+4.5%
EPS CAGR+1.8%
  1. 25 Jul 2026 · 12:39 PM IST Mercury Labs net profit plunges 69% as revenue slips in Q1
  2. 3d ago Mercury Labs profit dives 69% in Q1 as revenue slips 12%